AdvanSix | 10-Q: FY2025 Q3 Revenue: USD 374.47 M

Revenue: As of FY2025 Q3, the actual value is USD 374.47 M.

EPS: As of FY2025 Q3, the actual value is USD -0.1, missing the estimate of USD 1.03.

EBIT: As of FY2025 Q3, the actual value is USD -1.225 M.

Nylon Solutions:
- Nylon revenue was $79,029 (21%) for Q3 2025, compared to $93,693 (24%) for Q3 2024. For the nine months ended September 30, 2025, revenue was $246,900 (21%), compared to $281,299 (24%) for the same period in 2024.
- Caprolactam revenue was $73,137 (20%) for Q3 2025, compared to $76,338 (19%) for Q3 2024. For the nine months ended September 30, 2025, revenue was $206,993 (18%), compared to $219,117 (18%) for the same period in 2024.
Plant Nutrients: Revenue was $138,661 (37%) for Q3 2025, compared to $113,552 (29%) for Q3 2024. For the nine months ended September 30, 2025, revenue was $423,672 (36%), compared to $355,587 (30%) for the same period in 2024.
Chemical Intermediates: Revenue was $83,646 (22%) for Q3 2025, compared to $114,604 (28%) for Q3 2024. For the nine months ended September 30, 2025, revenue was $284,721 (25%), compared to $332,492 (28%) for the same period in 2024.

Net Income:
- Net income for Q3 2025 was - $2,638, compared to $22,266 for Q3 2024.
- For the nine months ended September 30, 2025, net income was $52,077, compared to $43,797 for the same period in 2024.
Gross Margin:
- Gross margin for Q3 2025 was 6.8%, compared to 14.4% for Q3 2024.
- For the nine months ended September 30, 2025, gross margin was 11.8%, compared to 11.9% for the same period in 2024.
Selling, General and Administrative Expenses:
- Expenses for Q3 2025 were $27,425, compared to $24,265 for Q3 2024.
- For the nine months ended September 30, 2025, expenses were $76,250, compared to $72,290 for the same period in 2024.
Income Tax Expense (Benefit):
- Income tax benefit for Q3 2025 was - $909, compared to an expense of $7,479 for Q3 2024.
- For the nine months ended September 30, 2025, income tax expense was $4,955, compared to $14,603 for the same period in 2024.

Operating Cash Flow:
- Operating cash flow for the nine months ended September 30, 2025, was $59,141, compared to $71,248 for the same period in 2024.
Investing Cash Flow:
- Investing cash flow for the nine months ended September 30, 2025, was - $95,002, compared to - $105,426 for the same period in 2024.
Financing Cash Flow:
- Financing cash flow for the nine months ended September 30, 2025, was $39,993, compared to $21,708 for the same period in 2024.
Net Change in Cash and Cash Equivalents:
- Net change in cash and cash equivalents for the nine months ended September 30, 2025, was $4,132, compared to - $12,470 for the same period in 2024.

Deferred Income and Customer Advances:
- Opening balance on January 1, 2025, was $37,538.
- Additional cash advances were $101.
- Amounts recognized in revenues were - $36,958.
- Ending balance on September 30, 2025, was $681.

Core Business Focus: The company plans to continue its focus on its core business areas, including Nylon Solutions, Plant Nutrients, and Chemical Intermediates. The company aims to maintain its leadership position in the production of caprolactam and ammonium sulfate fertilizers, leveraging its integrated value chain and large-scale manufacturing facilities. The company also plans to invest in strategic regulatory matters and potential inorganic growth options, as well as upgrading its enterprise resource planning system.
Non-Core Business: The company is actively pursuing strategic regulatory matters and potential inorganic growth options, which may include acquisitions or other business development activities. The company is also focused on optimizing its supply chain financing and trade receivables discount arrangements to enhance liquidity and manage working capital needs.
Priority: The company emphasizes disciplined capital deployment, with capital expenditures expected to be approximately $120 million to $125 million in 2025, reflecting the planned progression of its SUSTAIN growth program and refined execution timing to address critical enterprise risk mitigation.